Parikh Asit
Known title: DirectorCIK: 0001796787
Parikh Asit's purchase track record
How the stock did after each of Parikh Asit's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
8
of 8 since May 12, 2022
Stock higher 6 months later
100%
3 months: 75%
Median 6-month return
+71.3%
3 months: +51.0%
Beat the S&P 500
100%
median +64.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/6/2025 | PHAT | $25K | +249.2% | +462.1% | +20.8% |
| 3/13/2025 | PHAT | $44K | +137.7% | +185.8% | +19.3% |
| 12/13/2024 | PHAT | $81K | -44.1% | +34.8% | -1.2% |
| 11/6/2023 | PHAT | $59K | -16.0% | +36.4% | +18.7% |
| 4/10/2023 | PHAT | $8K | +73.4% | +31.1% | +5.5% |
| 2/13/2023 | PHAT | $39K | +58.4% | +93.8% | +8.5% |
| 1/12/2023 | PHAT | $35K | +43.6% | +94.0% | +13.2% |
| 5/12/2022 | PHAT | $100K | +32.1% | +48.7% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PHAT | ▼ Sell | Gift | 28,000 | $0 | 5/22/2026 | View on chart |
| PHAT | ▼ Sell | Gift | 28,000 | $0 | 5/22/2026 | View on chart |
| PHAT | ▲ Buy | Option Exercise | 17,500 | $87K | 5/20/2026 | View on chart |
| PHAT | ▲ Buy | Grant | 24,122 | $0 | 5/19/2026 | View on chart |
| PHAT | ▼ Sell | Gift | 40,000 | $0 | 3/10/2026 | View on chart |
| PHAT | ▼ Sell | Gift | 40,000 | $0 | 3/10/2026 | View on chart |
| PHAT | ▼ Sell | Gift | 80,500 | $0 | 1/23/2026 | View on chart |
| PHAT | ▼ Sell | Gift | 80,500 | $0 | 1/23/2026 | View on chart |
| PHAT | ▲ Buy | Option Exercise | 8,750 | $90K | 1/13/2026 | View on chart |
| PHAT | ▲ Buy | Option Exercise | 8,750 | $90K | 12/19/2025 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 6/3/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 5,000 | $12K | 5/7/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 5,000 | $13K | 5/6/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 10,000 | $44K | 3/13/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 10,000 | $81K | 12/13/2024 | View on chart |
| PHAT | ▲ Buy | Option Exercise | 7,500 | $88K | 9/10/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 5/23/2024 | View on chart |
| PHAT | ▲ Buy | Open Market | 2,500 | $20K | 11/8/2023 | View on chart |
| PHAT | ▲ Buy | Open Market | 4,000 | $31K | 11/7/2023 | View on chart |
| PHAT | ▲ Buy | Open Market | 1,000 | $8K | 11/6/2023 | View on chart |
| PHAT | ▲ Buy | Grant | 15,000 | $111K | 6/2/2023 | View on chart |
| PHAT | ▲ Buy | Grant | 9,000 | $0 | 5/25/2023 | View on chart |
| PHAT | ▲ Buy | Open Market | 1,000 | $8K | 4/10/2023 | View on chart |
| PHAT | ▲ Buy | Open Market | 5,000 | $39K | 2/13/2023 | View on chart |
| PHAT | ▲ Buy | Open Market | 5,000 | $35K | 1/12/2023 | View on chart |
| PHAT | ▲ Buy | Open Market | 12,500 | $100K | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD
Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.